Assessment of Three Basic Progressive Lens Designs

NCT ID: NCT05252871

Last Updated: 2024-08-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-09

Study Completion Date

2022-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial investigates the differences between three different progressive addition lens designs. It is a non-invasive double-masked randomized clinical investigation. For this study, 80 participants will be recruited.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to evaluate the preference, adaptability, and visual performance of three progressive lens designs. The difference in these lens designs is a variation of zone sizes for intermediate and near vision. The clinical trial helps manufacturers and eye care practitioners to give detailed suggestions to patients. Study participants will be experienced progressive addition lens wearers, which will be recruited by advertisements, by email, and with direct person-to-person solicitation. The study will be conducted at the Eye Care Institute at the Patient Care Center Western University of Health Sciences, Pomona, CA, 91766. For each participant, the study is completed in around two months and requires three separate visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Presbyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Progressive addition lens designs are unknown to participants, investigators, and outcomes assessors.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: The specified PAL design wearers

Subjects who have been already wearing any from specified design type of PAL

Group Type EXPERIMENTAL

Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating

Intervention Type DEVICE

Subjects will be wearing three different PAL designs with different geometries of the optical progression.

The other PAL design wearers

Subjects who have been already wearing any from the other design type of PAL

Group Type ACTIVE_COMPARATOR

Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating

Intervention Type DEVICE

Subjects will be wearing three different PAL designs with different geometries of the optical progression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating

Subjects will be wearing three different PAL designs with different geometries of the optical progression.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 45 to 70 years old.
* Visual Acuity: far \& near monocular: cc ≥ 20/20 (decimal cc ≥ 1.0)
* Normal binocular vision (at distance \& near: no strabismus on cover testing, aligning prism of less than 2Δ horizontally or vertically, stereoacuity of 2' or better at distance and near).
* Prescription is in the range:

* Spherical power: less than +/-6.00 D
* Cylindrical power: less than -2.75 D
* Addition: 1.50 D - 2.50 D
* Difference in power (spherical equivalent) between eyes: less than 2.00 D

Exclusion Criteria

* Have never worn any progressive lens design.
* First prescription for progressive lenses.
* Prescription found during visit#1 varies from current prescription more than 0.50 D in any meridian.
* Currently wearing single vision lenses with accommodative support.
* Double vision or prismatic prescription in current glasses.
* Known ocular disease including strabismus, any pathology, any eye surgeries that may affect visual acuity.
* Use of systemic or ocular medications that are likely to affect vision.
* Balance problem/vertigo problem.
* Concurrent participation in other vision-related research.
Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoya Vision Care

INDUSTRY

Sponsor Role collaborator

Western University of Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frank Spors, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Western University of Health Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Western University of Health Sciences

Pomona, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P21/IRB/065

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.